Tetrahydrocannabinol potentiates reserpine-induced hypokinesia.                   (abst – 1981)


Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia.                                                       (abst – 1985)


Open label evaluation of cannabidiol in dystonic movement disorders.                   (full – 1986)


The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson’s disease (PD).                                                                 (abst – 1998)


Cannabinoids in parkinsonism                        (3 abstracts – 1999)


Cannabis in movement disorders.                 (abst – 1999)


Why your brain is primed for a high                (news – 1999)    (may need registration)


Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease                                                           (full – 2000)  cannabis&andorexactfulltext=and&searchid=1&FIRSTINDEX=20&sortspec=relevance&resourcetype=H   WCIT


Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.                                                          (full – 2002)


US Patent 6630507 – Cannabinoids as antioxidants and neuroprotectants             (full – 2003)


Therapeutic potential of cannabinoids in CNS disease.               (abst – 2003)


Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms.         (abst – 2004)


Marijuana Compounds May Aid Parkinson’s Disease              (news – 2004)


Depression in Parkinson’s disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)                                                                        (full – 2005)


Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease.                                               (abst – 2005)


Cannabinoid control of motor function at the basal ganglia.              (abst – 2005)


Cannabinoids In Medicine: A Review Of Their Therapeutic Potential                  (full – 2006)


Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson’s disease: role of CB1 and TRPV1 receptors                                                   (full – 2007)


The endocannabinoid system in targeting inflammatory neurodegenerative diseases (full – 2007) ry_neuro.pdf


Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties. (abst – 2007)                           


Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease models.       (abst – 2007)                    


Cannabinoids and neuroprotection in motor-related disorders.              (abst – 2007)


Marijuana Against Parkinson?               (news – 2007)


Marijuana-Like Chemicals Helps Treat Parkinson’s                (news – 2007)


Parkinsons’ Helped By Marijuana-Like Chemicals In Brain               (news – 2007)


Enhancing Activity Of Marijuana-Like Chemicals In Brain Helps Treat Parkinson’s Symptoms In Mice   (news – 2007)


Paraquat induces apoptosis in human lymphocytes: protective and rescue effects of glucose, cannabinoids and insulin-like growth factor-1.                                                         (abst – 2008)


The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson’s disease. (abst – 2008)


LSUHSC research reports new method to protect brain cells from diseases like Alzheimer’s          (news – 2008)                       


WIN55,212-2, a Cannabinoid Receptor Agonist, Protects Against Nigrostriatal Cell Loss in the MPTP Mouse Model of Parkinson’s Disease                                                 (full – 2009)


Cannabidiol: a promising drug for neurodegenerative disorders?              (full – 2009)


The endocannabinoid system as a target for the treatment of motor dysfunction. (abst – 2009)   nel.Pubmed_RVDocSum&ordinalpos=54


Cannabidiol for the treatment of psychosis in Parkinson’s disease               (abst – 2009)  t=cannabinoid&searchid=1&FIRSTINDEX=1920&resourcetype=HWCIT


Medical Marijuana and Parkinson’s Disease                (news – 2009)


Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders      (full – 2010)                 


Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.                                                            (full – 2010)


Cannabinoids and Dementia: A Review of Clinical and Preclinical Data (link to PDF – 2010)                                     


Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson’s disease in the rat.                                                            (abst – 2010)


Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction.                                         (full – 2011)


Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011)                        


Prospects for cannabinoid therapies in basal ganglia disorders.              (full – 2011)


Therapeutic Potential of Cannabinoids in the Treatment of Neuroinflammation Associated with Parkinson’s Disease                                                                             (abst – 2011)  abinoids_in_the_Treatment_of_Neuroinflammation_Associated_with_Parkinson%27s_Disease_


Regional changes in type 1 cannabinoid receptor availability in Parkinson’s disease in vivo           (abst – 2011)  annabinoid_receptor_availability_in_Parkinson%27s_disease_in_vivo_


Homeostatic changes of the endocannabinoid system in Parkinson’s disease. (abst – 2011) ndocannabinoid_system_in_Parkinson%27s_disease_


Symptom-relieving and neuroprotective effects of the phytocannabinoid D(9) -THCV in animal models of Parkinson’s disease                                            (abst – 2011)





Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation.                                                              (abst – 2011)


New metabolic pathway for controlling brain inflammation                        (news – 2011)  inflammation.aspx


The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription (full – 2012)                                  


Cannabinoid modulation of neuroinflammatory disorders.                    (full – 2012)


Review article: The endocannabinoid system in normal and pathological brain ageing (abst – 2012)                                  


The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.                                                           (abst – 2012)


Δ(9) -THC exerts a direct neuroprotective effect in a human cell culture model of Parkinson’s disease.     (abst – 2012)                                 


The decrease of dopamine D(2)/D(3) receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB(1) cannabinoid receptors in Parkinson’s disease: A preliminary autoradiographic study with the selective dopamine D(2)/D(3) antagonist [(3)H]raclopride and the novel CB(1) inverse agonist [(125)I]SD7015.                                                (abst – 2012)


Cannabinoids and value-based decision making: implications for neurodegenerative disorders.    (abst – 2012)                         


Contribution of genetic variants to pain susceptibility in Parkinson disease

(abst – 2012)          

Share a link for